TSAM
VRTX icon

Trinity Street Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Trinity Street Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-116,612
Closed -$25.5M – 20
2019
Q4 		$25.5M Buy
+116,612
New +$23.6M 3.46% 18

Other funds holding VRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Trinity Street Asset Management's VRTX Position: Q1 2020 in Review

Trinity Street Asset Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2020, closing a stake of 116,612 shares — an estimated $25.5M sold.

Trinity Street Asset Management first reported a position in VRTX in Q4 2019 and held it in 1 quarter. The position peaked at $25.5M in Q4 2019. 854 funds tracked by Wall St. Rank hold VRTX as of Q1 2020.

  • Trinity Street Asset Management reported no remaining Vertex Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Trinity Street Asset Management sold 116,612 Vertex Pharmaceuticals shares in Q1 2020, an estimated $25.5M.
  • Trinity Street Asset Management first reported a position in Vertex Pharmaceuticals in Q4 2019 and held it in 1 quarter.
  • Trinity Street Asset Management's Vertex Pharmaceuticals position peaked at $25.5M in Q4 2019.
  • 854 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2020.

Based on Trinity Street Asset Management's 13F filing for Q1 2020, filed 22 Apr 2020.